RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 79.1%

Neg 79.1% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $4 to $3.